P4-183: A human in vitro blood-brain barrier model for measuring drug transport in Alzheimer's disease

2015 ◽  
Vol 11 (7S_Part_18) ◽  
pp. P850-P850 ◽  
Author(s):  
Jennifer L. Mantle ◽  
Kelvin H. Lee
2012 ◽  
Vol 15 (2) ◽  
pp. 324-336 ◽  
Author(s):  
Kwok Kin Cheng ◽  
Chin Fung Yeung ◽  
Shuk Wai Ho ◽  
Shing Fung Chow ◽  
Albert H. L. Chow ◽  
...  

2020 ◽  
Vol 37 (10) ◽  
Author(s):  
Aikaterini Lalatsa ◽  
Yujiao Sun ◽  
Jose Ignacio Gamboa ◽  
Shira Knafo

Abstract Purpose Amyloid β (Aβ) drives the accumulation of excess Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) at synapses, inducing synaptic depression and perturbing memory. This recruitment of PTEN to synapses in response to Aβ drives its interaction with PSD95/Disc large/Zonula occludens-1 (PDZ) proteins and, indeed, we previously showed that an oligo lipopeptide (PTEN-PDZ) capable of blocking such PTEN:PDZ interactions rescues the synaptic and cognitive deficits in a mouse model of Alzheimer’s disease. Hence, the PTEN:PDZ interaction appears to be crucial for Aβ-induced synaptic and cognitive impairment. Here we have evaluated the feasibility of using PTEN-PDZ lipopeptides based on the human/mouse PTEN C-terminal sequence, testing their stability in biological fluids, their cytotoxicity, their ability to self-assemble and their in vitro blood-brain barrier (BBB) permeability. Myristoyl or Lauryl tails were added to the peptides to enhance their cell permeability. Methods Lipopeptides self assembly was assessed using electron microscopy and the thioflavin T assay. Stability studies in mouse plasma (50%), intestinal washing, brain and liver homogenates as well as permeability studies across an all human 2D blood-brain barrier model prepared with human cerebral endothelial cells (hCMEC/D3) and human astrocytes (SC-1800) were undertaken. Results The mouse lauryl peptide displayed enhanced overall stability in plasma, ensuring a longer half-life in circulation that meant there were larger amounts available for transport across the BBB (Papp0-4h: 6.28 ± 1.85 × 10−6 cm s−1). Conclusion This increased availability, coupled to adequate BBB permeability, makes this peptide a good candidate for therapeutic parenteral (intravenous, intramuscular) administration and nose-to-brain delivery. Graphical Abstract


1995 ◽  
Vol 9 (4) ◽  
pp. 357-364 ◽  
Author(s):  
B. Joly ◽  
O. Fardel ◽  
R. Cecchelli ◽  
C. Chesné ◽  
C. Puozzo ◽  
...  

2020 ◽  
Vol 12 (3) ◽  
pp. 035008
Author(s):  
Libiao Liu ◽  
Xinda Li ◽  
Xinzhi Zhang ◽  
Tao Xu

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi49-vi50
Author(s):  
Choi-Fong Cho ◽  
Justin Wolfe ◽  
Colin Fazden ◽  
Kalvis Hornburg ◽  
E. Antonio Chiocca ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document